Welcome to
Издательство Атмосфера

· Журналы
· Книги
· О проекте

·Электронные версии книг издательства “Атмосфера” поступили в продажу

Издательство “Атмосфера” идет в ногу со временем и открывает на своем сайте раздел электронных версий своих книг. Теперь вы можете приобрести не только традиционную бумажную книгу в картонном переплете, но и .pdf-файл, снабженный гиперссылками на каждую главу издания. В электронной версии проще отыскать рисунок и таблицу. Чтобы обратиться к ним, достаточно нажать на ссылку на каждый из них. Исчезла зависимость от тиража – вы можете приобрести даже те бестселлеры, тираж которых уже разошелся, такие как “Саркоидоз” или “Заболевания органов дыхания при беременности”. Упростилось получение вами книг – в течение двух рабочих дней после оплаты требуемые файлы придут на ваш e-mail. Ну и наконец, цена – электронные версии наших книг гораздо дешевле, чем бумажные издания. Заказывайте электронные версии книг издательства “Атмосфера” на сайте, а также по телефону: (495) 730-63-51 и по e-mail: atm-press2012@yandex.ru


ИНТЕРНЕТ-МАГАЗИН
Издательство Атмосфера


Телефон издательства

  
Практическая пульмонология (ранее – "Атмосфера. Пульмонология и аллергология"): ISSN 2409-756X (Online), ISSN 2409-6636 (Print)
2019 / N 3

Опыт применения дупилумаба в комплексной терапии бронхиальной астмы и атопического дерматита у взрослых в реальной клинической практике: обзор литературы и клинические примеры
Д.С. Фомина, С.А. Сердотецкова, М.К. Гаджиева, Л.С. Луценко

References

1. Coca AF, Cooke RA. On the classification of the phenomena of hypersensitiveness. The Journal of Immunology 1923 May;8(3):163-82.
2. Bantz SK, Zhu Z, Zheng T. The atopic march: progression from atopic dermatitis to allergic rhinitis and asthma. Journal of Clinical & Cellular Immunology 2014 Apr;5(2). pii: 202.
3. Barnetson RS, Rogers M. Childhood atopic eczema. BMJ 2002 Jun;324(7350):1376-9.
4. Global Initiative for Asthma (GINA). Diagnosis and management of difficult-to-treat and severe asthma. Available from: https://ginasthma.org/severeasthma/ Accessed 2019 Dec 12.
5. Bousquet J, Khaltaev N, Cruz AA, Denburg J, Fokkens WJ, Togias A, Zuberbier T, Baena-Cagnani CE, Canonica GW, van Weel C, Agache I, Aït-Khaled N, Bachert C, Blaiss MS, Bonini S, Boulet LP, Bousquet PJ, Camargos P, Carlsen KH, Chen Y, Custovic A, Dahl R, Demoly P, Douagui H, Durham SR, van Wijk RG, Kalayci O, Kaliner MA, Kim YY, Kowalski ML, Kuna P, Le LT, Lemiere C, Li J, Lockey RF, Mavale-Manuel S, Meltzer EO, Mohammad Y, Mullol J, Naclerio R, O’Hehir RE, Ohta K, Ouedraogo S, Palkonen S, Papadopoulos N, Passalacqua G, Pawankar R, Popov TA, Rabe KF, Rosado-Pinto J, Scadding GK, Simons FE, Toskala E, Valovirta E, van Cauwenberge P, Wang DY, Wickman M, Yawn BP, Yorgancioglu A, Yusuf OM, Zar H, Annesi-Maesano I, Bateman ED, Ben Kheder A, Boakye DA, Bouchard J, Burney P, Busse WW, Chan-Yeung M, Chavannes NH, Chuchalin A, Dolen WK, Emuzyte R, Grouse L, Humbert M, Jackson C, Johnston SL, Keith PK, Kemp JP, Klossek JM, Larenas-Linnemann D, Lipworth B, Malo JL, Marshall GD, Naspitz C, Nekam K, Niggemann B, Nizankowska-Mogilnicka E, Okamoto Y, Orru MP, Potter P, Price D, Stoloff SW, Vandenplas O, Viegi G, Williams D; World Health Organization; GA(2)LEN; AllerGen. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen). Allergy 2008 Apr;63(Suppl 86):8-160.
6. Johansson SGO, Hourihane J, Bousquet J, Bruijnzeel‐Koomen C, Dreborg S, Haahtela T, Kowalski ML, Mygind N, Ring J, Van Cauwenberge P, Van Hage‐Hamsten M, Wüthrich B. A revised nomenclature for allergy: an EAACI position statement from the EAACI nomenclature task force. Allergy 2008 Jul;56:813-24.
7. Thomsen SF. Epidemiology and natural history of atopic diseases. European Clinical Respiratory Journal 2015 Mar 24;2. doi: 10.3402/ecrj.v2.24642. eCollection 2015.
8. Simpson EL, Bieber T, Eckert L, Wu R, Ardeleanu M, Graham NM, Pirozzi G, Mastey V. Patient burden of moderate to severe atopic dermatitis (AD): insights from a phase 2b clinical trial of dupilumab in adults. Journal of the American Academy of Dermatology 2016 Mar;74(3):491-8.
9. Matsusaka M, Kabata H, Fukunaga K, Suzuki Y, Masaki K, Mochimaru T, Sakamaki F, Oyamada Y, Inoue T, Oguma T, Sayama K, Koh H, Nakamura M, Umeda A, Ono J, Ohta S, Izuhara K, Asano K, Betsuyaku T. Phenotype of asthma related with high serum periostin levels. Allergology International 2015 Apr;64(2):175-80.
10. Tan BK, Chandra RK, Pollak J, Kato A, Conley DB, Peters AT, Grammer LC, Avila PC, Kern RC, Stewart WF, Schleimer RP, Schwartz BS. Incidence and associated premorbid diagnoses of patients with chronic rhinosinusitis. The Journal of Allergy and Clinical Immunology 2013 May;131(5):1350-60.
11. Pearlman AN, Chandra RK, Chang D, Conley DB, Tripathi-Peters A, Grammer LC, Schleimer RT, Kern RC. Relationships between severity of chronic rhinosinusitis and nasal polyposis, asthma, and atopy. American Journal of Rhinology & Allergy 2009 Mar-Apr;23(2):145-8.
12. Heffler E, Blasi F, Latorre M, Menzella F, Paggiaro P, Pelaia G, Senna G, Canonica GW; SANI Network. The severe asthma network in Italy: findings and perspectives. The Journal of Allergy and Clinical Immunology. In Practice 2019 May-Jun;7(5):1462-8.
13. Shokouhi Shoormasti R, Pourpak Z, Fazlollahi MR, Kazemnejad A, Nadali F, Ebadi Z, Tayebi B, Moslemi M, Karimi A, Valmohammadi S, Nazemi AM, Mari A, Moin M. The prevalence of allergic rhinitis, allergic conjunctivitis, atopic dermatitis and asthma among adults of Tehran. Iranian Journal of Public Health 2018 Nov;47(11):1749-55.
14. Arabkhazaeli A, Vijverberg JH, van Erp FC, Raaijmakers JAM, van der Ent CK, van der Maitland Zee AH. Characteristics and severity of asthma in children with and without atopic conditions: a cross-sectional study. BMC Pediatrics 2015 Dec;15(1):172.
15. Whiteley J, Emir B, Seitzman R, Makinson G. The burden of atopic dermatitis in US adults: results from the 2013 National Health and Wellness Survey. Current Medical Research and Opinion 2016 Oct;32(10):1645-51.
16. Haselkorn T, Chen H, Miller DP, Fish JE, Peters SP, Weiss ST, Jones CA. Asthma control and activity limitations: insights from the Real-world Evaluation of Asthma Control and Treatment (REACT) study. Annals of Allergy, Asthma & Immunology 2010 Jun;104(6):471-7.
17. Schleich F, Brusselle G, Louis R, Vandenplas O, Michils A, Pilette C, Peche R, Manise M, Joos G. Heterogeneity of phenotypes in severe asthmatics. The Belgian Severe Asthma Registry (BSAR). Respiratory Medicine 2014 Dec;108(12):1723-32.
18. Tay TR, Radhakrishna N, Hore-Lacy F, Smith C, Hoy R, Dabscheck E, Hew M. Comorbidities in difficult asthma are independent risk factors for frequent exacerbations, poor control and diminished quality of life. Respirology 2016 Nov;21(8):1384-90.
19. Langdon C, Mullol J. Nasal polyps in patients with asthma: prevalence, impact, and management challenges. Journal of Asthma and Allergy 2016 Mar;9:45-53.
20. Blakey JD, Price DB, Pizzichini E, Popov TA, Dimitrov BD, Postma DS, Josephs LK, Kaplan A, Papi A, Kerkhof M, Hillyer EV, Chisholm A, Thomas M. Identifying risk of future asthma attacks using UK medical record data: a Respiratory Effectiveness Group Initiative. The Journal of Allergy and Clinical Immunology. In Practice 2017 Jul-Aug;5(4):1015-24.e8.
21. Denlinger LC, Phillips BR, Ramratnam S, Ross K, Bhakta NR, Cardet JC, Castro M, Peters SP, Phipatanakul W, Aujla S, Bacharier LB, Bleecker ER, Comhair SA, Coverstone A, DeBoer M, Erzurum SC, Fain SB, Fajt M, Fitzpatrick AM, Gaffin J, Gaston B, Hastie AT, Hawkins GA, Holguin F, Irani AM, Israel E, Levy BD, Ly N, Meyers DA, Moore WC, Myers R, Opina MT, Peters MC, Schiebler ML, Sorkness RL, Teague WG, Wenzel SE, Woodruff PG, Mauger DT, Fahy JV, Jarjour NN; National Heart, Lung, and Blood Institute’s Severe Asthma Research Program-3 Investigators. Inflammatory and comorbid features of patients with severe asthma and frequent exacerbations. American Journal of Respiratory and Critical Care Medicine 2017 Feb 1;195(3):302-13.
22. Silverberg JI. Comorbidities and the impact of atopic dermatitis. Annals of Allergy, Asthma & Immunology 2019 Aug;123(2):144-51.
23. Ek A, Middelveld RJ, Bertilsson H, Bjerg A, Ekerljung L, Malinovschi A, Stjärne P, Larsson K, Dahlén SE, Janson C. Chronic rhinosinusitis in asthma is a negative predictor of quality of life: results from the Swedish GA(2)LEN survey. Allergy 2013 Oct;68(10):1314-21.
24. Hoskins G, Williams B, Abhyankar P, Donnan P, Duncan E, Pinnock H, van der Pol M, Rauchhaus P, Taylor A, Sheikh A. Achieving Good Outcomes for Asthma Living (GOAL): mixed methods feasibility and pilot cluster randomised controlled trial of a practical intervention for eliciting, setting and achieving goals for adults with asthma. Trials 2016 Dec;17(1):584.
25. Alobid I, Benítez P, Bernal-Sprekelsen M, Roca J, Alonso J, Picado C, Mullol J. Nasal polyposis and its impact on quality of life: comparison between the effects of medical and surgical treatments. Allergy 2005 Apr;60(4):452-8.
26. Aguilar D, Pinart M, Koppelman GH, Saeys Y, Nawijn MC, Postma DS, Akdis M, Auffray C, Ballereau S, Benet M, García-Aymerich J, González JR, Guerra S, Keil T, Kogevinas M, Lambrecht B, Lemonnier N, Melen E, Sunyer J, Valenta R, Valverde S, Wickman M, Bousquet J, Oliva B, Antó JM. Computational analysis of multimorbidity between asthma, eczema and rhinitis. PloS One 2017 Jun 9;12(6):e0179125.
27. Gandhi NA, Bennett BL, Graham NM, Pirozzi G, Stahl N, Yancopoulos GD. Targeting key proximal drivers of type 2 inflammation in disease. Nature Reviews. Drug Discovery 2016 Jan;15(1):35-50.
28. Instructions for medical use of the drug Dupixent® (dupilumab). Registration number LP-005440 dated 2019 Apr 04 (In Russian).
29. Robinson D, Humbert M, Buhl R, Cruz AA, Inoue H, Korom S, Hanania NA, Nair P. Revisiting type 2-high and type 2-low airway inflammation in asthma: current knowledge and therapeutic implications. Clinical & Experimental Allergy 2017 Feb;47(2):161-75.
30. Hammad H, Lambrecht BN. Dendritic cells and epithelial cells: linking innate and adaptive immunity in asthma. Nature Review Immunology 2008 Mar;8(3):193-204.
31. Simpson EL, Bieber T, Guttman-Yassky E, Beck LA, Blauvelt A, Cork MJ, Silverberg JI, Deleuran M, Kataoka Y, Lacour JP, Kingo K, Worm M, Poulin Y, Wollenberg A, Soo Y, Graham NM, Pirozzi G, Akinlade B, Staudinger H, Mastey V, Eckert L, Gadkari A, Stahl N, Yancopoulos GD, Ardeleanu M; SOLO 1 and SOLO 2 Investigators. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. The New England Journal of Medicine 2016 Dec;375(24):2335-48.
32. Blauvelt A, de Bruin-Weller M, Gooderham M, Cather JC, Weisman J, Pariser D, Simpson EL, Papp KA, Hong HC, Rubel D, Foley P, Prens E, Griffiths CEM, Etoh T, Pinto PH, Pujol RM, Szepietowski JC, Ettler K, Kemény L, Zhu X, Akinlade B, Hultsch T, Mastey V, Gadkari A, Eckert L, Amin N, Graham NMH, Pirozzi G, Stahl N, Yancopoulos GD, Shumel B. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial. The Lancet 2017 Jun;389(10086):2287-303.
33. de Bruin-Weller M, Thaçi D, Smith CH, Reich K, Cork MJ, Radin A, Zhang Q, Akinlade B, Gadkari A, Eckert L, Hultsch T, Chen Z, Pirozzi G, Graham NMH, Shumel B. Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo-controlled, randomized phase III clinical trial. The British Journal of Dermatology 2018 May;178(5):1083-101.
34. Rehal B, Armstrong AW. Health outcome measures in atopic dermatitis: a systematic review of trends in disease severity and quality-of-life instruments 1985-2010. PLoS One 2011 Apr 13;6(4):e17520.
35. Harmonizing Outcome Measures for Eczema (HOME). EASI (Eczema Area and Severity Index) guidance 2017 Jan. Available from: http://www.homeforeczema.org/documents/easi-user-guide-jan-2017-v3.pdf. Accessed 2019 Dec 12.
36. Hanifin JM, Thurston M, Omoto M, Cherill R, Tofte SJ, Graeber M; EASI Evaluator Group. The eczema area and severity index (EASI): assessment of reliability in atopic dermatitis. Experimental Dermatology 2008 Jul;10(1):11-8.
37. Oranje AP, Glazenburg EJ, Wolkerstorfer A, de Waard-van der Spek FB. Practical issues on interpretation of scoring atopic dermatitis: the SCORAD index, objective SCORAD and the three-item severity score. The British Journal of Dermatology 2007 Oct;157(4):645-8.
  

[ Содержание выпуска N 3 | Выпуски журнала | Список журналов ]